Effects of S-Amlodipine in the Management of Hypertension in Mongolian Patients
Manish Maladkar
Department of Scientific, Aristo Pharmaceuticals Private Limited, India.
Javzankhuu Amarsanaa
Department of Cardiology, Second State Central Hospital, Mongolia.
Orgil Sengeragchaa
Department of Internal Medicine, Darkhan General Hospital, Darkhan-Uul Province, Mongolia.
Shrikant Patil
Department of Scientific, Aristo Pharmaceuticals Private Limited, India.
Namita Anchan *
Department of Scientific, Aristo Pharmaceuticals Private Limited, India.
*Author to whom correspondence should be addressed.
Abstract
Objective: To evaluate the efficacy and safety of S-Amlodipine in patients suffering from hypertension.
Materials and Methods: A multicenter, prospective, open-label, non-comparative, clinical trial was conducted on 364 patients with hypertension in Mongolia. All these patients were treated with S- Amlodipine 2.5 mg or 5 mg orally once daily for a duration of 8 weeks.
Results: S-Amlodipine treatment resulted in a considerable drop in blood pressure from baseline. After 8 weeks of treatment, the mean systolic blood pressure had decreased by 12.06 mmHg and the mean diastolic blood pressure had decreased by 8.77 mmHg. Furthermore, both physicians and patients assessed the overall efficacy and rated it as good. Also, during the therapy period, 6 individuals (1.7%) experienced minor or slight adverse symptoms such as cough and headache.
Conclusion: The current study confirms that treatment with S-Amlodipine was effective and well-tolerated in the management of hypertension.
Keywords: Hypertension, S-Amlodipine, blood pressure, amlodipine, Mongolia, cardiovascular diseases